The FDA Has Granted Breakthrough Therapy Designation For Precigen's PRGN-2012 Adenoverse Immunotherapy For Recurrent Respiratory Papillomatosis
Portfolio Pulse from Benzinga Newsdesk
The FDA has granted Breakthrough Therapy Designation for Precigen's PRGN-2012 Adenoverse Immunotherapy for Recurrent Respiratory Papillomatosis, potentially accelerating the development and review process.
June 20, 2023 | 11:32 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Precigen's PRGN-2012 Adenoverse Immunotherapy receives FDA Breakthrough Therapy Designation, potentially speeding up development and review.
The FDA Breakthrough Therapy Designation is granted to expedite the development and review of drugs that show potential to treat serious or life-threatening conditions. This designation for Precigen's PRGN-2012 Adenoverse Immunotherapy for Recurrent Respiratory Papillomatosis is likely to have a positive short-term impact on the company's stock price, as it demonstrates the potential of the therapy and may accelerate its development and review process.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100